Abhay Joshi, Ph.D. MBA
Board Member
Dr. Abhay Joshi brings over thirty years of global experience as a pharmaceutical and biotechnology executive. He currently serves as the President & CEO at Axent Biosciences. Before joining Axent , he held the position of COO and President of R&D and Product Operations at Revance Therapeutics from 2015 to 2022. During this period, he contributed to the development and commercialization of aesthetic and therapeutic products. From 2007 to 2015, Dr. Joshi served as the President and CEO of Alvine Pharmaceuticals, a clinical-stage company focusing on biologics for autoimmune and inflammatory diseases. Earlier in his career, he served as an Executive Vice President and CTO at CoTherix, Inc., a company later acquired by Actelion Ltd in 2007. He also held the position of Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan, Inc. His responsibilities included overseeing global biologics manufacturing operations for BOTOX® and managing Latin America and Asia Pacific pharmaceutical operations. Dr. Joshi's contributions extend to his role on the Boards of Genyous Biomed, Sira Pharmaceuticals, and Sinopia Biosciences Inc. Recognized for his achievements, he was inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows Class of 2016. He earned his B.Tech in Chemical Engineering from the Indian Institute of Technology (IIT), New Delhi, an M.S.E. and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an M.B.A. from the University of California, Irvine.